Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Surprisingly, aPL status does not appear to be associated with the variation observed (Figure 4B), p = 0.3 In addition, aPL titres; complement; HCQ use and vitamin D insufficiency (<50 nmol/L) are not associated with variation across PC1 (Figure S3).

Source: Hierarchical clustering identifies four distinct patient clusters according to cytokine profile. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

A pro‐inflammatory cytokine signature characterises thrombotic antiphospholipid syndrome despite stable anticoagulation

Study design awaiting verification · British Journal of Haematology · 2026

Original publication title

A pro‐inflammatory cytokine signature characterises thrombotic antiphospholipid syndrome despite stable anticoagulation

Catherine B. Ducker; Megan V. Preece; Jeremy Schofield; Charis Pericleous; Mike Laffan; Simon Abrams; Deepa J. Arachchillage

© 2026 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Summary

Inflammation contributes to primary antiphospholipid syndrome (PAPS) pathogenesis, but cytokine profiles and associated thrombotic phenotypes remain incompletely defined. A panel of 20 cytokines, chemokines and endothelial activation markers was analysed in 37 PAPS patients on stable anticoagulation and 12 healthy controls (HC). We compared concentrations between groups and performed unsupervised hierarchical clustering and principal component analysis (PCA) to identify inflammatory subgroups. Compared with HC, patients with PAPS exhibited significantly elevated levels of 14/20 analytes: granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), interferon (IFN)‐γ, interleukin (IL)‐1α, IL‐1β, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐17a, tumour necrosis factor‐α (TNF‐α), intercellular adhesion molecule‐1 (ICAM‐1), P‐selectin and macrophage inflammatory protein‐1β (MIP1β) (all p < 0.05).

Unsupervised clustering identified three inflammatory antiphospholipid syndrome (APS) subgroups distinct from HC. A core cytokine signature comprising GM‐CSF, IL‐6, IL‐10, IL‐12p70, IL‐13 and TNF‐α was elevated across all APS clusters. One cluster, enriched for arterial thrombosis, demonstrated a more pronounced inflammatory phenotype, with increased IFN‐α. Comparison of phenotypes showed significantly higher concentrations of GM‐CSF, IFN‐α, IL‐1α, IL‐4, IL‐6, IL‐10, IL‐17a and TNF‐α in arterial versus venous thrombosis. Our findings demonstrate widespread cytokine dysregulation and distinct inflammatory subgroups in PAPS, with arterial thrombosis showing stronger inflammation than venous thrombosis, supporting divergent thrombo‐inflammatory mechanisms and potential precision immunomodulatory therapeutic targets.

Authors’ abstract

Summary

Inflammation contributes to primary antiphospholipid syndrome (PAPS) pathogenesis, but cytokine profiles and associated thrombotic phenotypes remain incompletely defined. A panel of 20 cytokines, chemokines and endothelial activation markers was analysed in 37 PAPS patients on stable anticoagulation and 12 healthy controls (HC). We compared concentrations between groups and performed unsupervised hierarchical clustering and principal component analysis (PCA) to identify inflammatory subgroups. Compared with HC, patients with PAPS exhibited significantly elevated levels of 14/20 analytes: granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), interferon (IFN)‐γ, interleukin (IL)‐1α, IL‐1β, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐17a, tumour necrosis factor‐α (TNF‐α), intercellular adhesion molecule‐1 (ICAM‐1), P‐selectin and macrophage inflammatory protein‐1β (MIP1β) (all p < 0.05).

Unsupervised clustering identified three inflammatory antiphospholipid syndrome (APS) subgroups distinct from HC. A core cytokine signature comprising GM‐CSF, IL‐6, IL‐10, IL‐12p70, IL‐13 and TNF‐α was elevated across all APS clusters. One cluster, enriched for arterial thrombosis, demonstrated a more pronounced inflammatory phenotype, with increased IFN‐α. Comparison of phenotypes showed significantly higher concentrations of GM‐CSF, IFN‐α, IL‐1α, IL‐4, IL‐6, IL‐10, IL‐17a and TNF‐α in arterial versus venous thrombosis. Our findings demonstrate widespread cytokine dysregulation and distinct inflammatory subgroups in PAPS, with arterial thrombosis showing stronger inflammation than venous thrombosis, supporting divergent thrombo‐inflammatory mechanisms and potential precision immunomodulatory therapeutic targets.

Publication and source details

Original title: A pro‐inflammatory cytokine signature characterises thrombotic antiphospholipid syndrome despite stable anticoagulation

Catherine B. Ducker; Megan V. Preece; Jeremy Schofield; Charis Pericleous; Mike Laffan; Simon Abrams; Deepa J. Arachchillage

British Journal of Haematology · 2026

* Correspondence
Deepa J. Arachchillage, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, 5th Floor, Commonwealth Building, Du Cane Road, London W12 0NN, United Kingdom.
Email: d.arachchillage@imperial.ac.uk
© 2026 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Medical Research Council UK MR/Z505274/1 NIHR Imperial Biomedical Research Centre10.13039/501100013342

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-13T04:45:18.865632+00:00

DOI: 10.1111/bjh.70816 · PMC13748370